Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study

被引：0
|
作者：
Zhou, F. [1 ]
Yang, L. [1 ]
Peng, J. [1 ]
Xu, H. [1 ]
Wu, H. [1 ]
Wang, Y. [1 ]
Long, X. [1 ]
Gao, Q. [2 ]
Shi, X. [3 ]
Gong, J. [4 ]
Hu, J. [3 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat Oncol Med Oncol, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[2] Huangmei Cty Peoples Hosp, Dept Radiat Oncol, Huanggang, Peoples R China
[3] Macheng Peoples Hosp, Dept Med Oncol, Macheng, Peoples R China
[4] Huangshi Cent Hosp, Dept Med Oncol, Huangshi, Hubei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
974P
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [31] A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
    Qin, Shukui
    Finn, Richard S.
    Kudo, Masatoshi
    Meyer, Tim
    Vogel, Arndt
    Ducreux, Michel
    Mercade, Teresa Macarulla
    Tomasello, Gianluca
    Boisserie, Frederic
    Hou, Jeannie
    Li, Cindy
    Song, James
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
  • [33] Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
    Qin, Shukui
    Li, Jin
    Zhong, Haijun
    Jin, Chuan
    Chen, Lili
    Yuan, Xianglin
    Fan, Qingxia
    Chen, Kehe
    Cao, Peiguo
    Xiao, Jianjun
    Jiang, Da
    Zhang, Tao
    Zhang, Hongyu
    Wang, Xicheng
    Wang, Wei
    Han, Lin
    Wang, Qingyu
    Zhu, Jun
    BRITISH JOURNAL OF CANCER, 2022, 127 (12) : 2241 - 2248
  • [34] Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
    Wang, Jing
    Li, Siqi
    Jiang, Hao
    Chang, Ying-Jun
    Zhao, Xiao-Su
    Jia, Jin-Song
    Zhu, Xiao-Lu
    Gong, Li-Zhong
    Liu, Xiao-Hong
    Yu, Wen-Jing
    Huang, Xiao-Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [36] An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)
    Raoul, J. L.
    Finn, R. S.
    Kang, Y. K.
    Park, J. W.
    Harris, R.
    Coric, V.
    Donica, M.
    Walters, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance A case report
    Zhu, Hong
    Yang, Xi
    Zhao, Yaqin
    Yi, Cheng
    MEDICINE, 2019, 98 (20)
  • [38] Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC)
    Zhou, Jian
    Yan, Zhiping
    Wang, Zheng
    Qiu, Shuang-Jian
    Yang, Minjie
    Zhu, Kai
    Yi, Yong
    Yu, Lei
    Sun, Yun-Fan
    Zhang, Bo
    Yu, Jiaze
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
    Xu, Jianming
    Xu, Nong
    Bai, Yuxian
    Liu, Rongrui
    Mao, Chenyu
    Sui, Hong
    Wang, Xiaofei
    Jiang, Qian
    Dou, Yiwei
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [40] Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy
    Julian, Cristina
    Machado, Robson J. M.
    Girish, Sandhya
    Chanu, Pascal
    Heinzmann, Dominik
    Harbron, Chris
    Gershon, Anda
    Pfeiffer, Shannon M.
    Zou, Wei
    Quarmby, Valerie
    Zhang, Qing
    Chen, Yachi
    CANCER REPORTS, 2022, 5 (10)
12345